Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Arthritis Research & Therapy

Figure 6

From: Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop

Figure 6

Formation of CCL2 and versican complex in circulating monocytes. (A) CCL2 was incubated with plastic plates coated with chondroitin sulfate (CS) or vehicle. Bound CCL2 was recovered and subjected to immunoblots (lanes 2 and 3, respectively). Lane 1, untreated CCL2 as a positive control. A representative result from three experiments is shown. (B) Versican and CCL2 cellular localization in monocytes from an systemic sclerosis (SSc) patient, assessed by multi-color immunocytostaining: upper panel, CCL2 (green), versican (red), and their merged image; lower panel, goldin-97 (green), versican (red), and their merged image. Nuclei were counterstained with TO-PRO3 (blue). A representative result from three independent experiments is shown. Original magnification, ×600.

Back to article page